Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06934655 · ClinicalTrials.gov registry record · Phase 3
Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth
A Phase 3 study, sponsored by Children's Hospital Los Angeles.
- Not yet
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT06934655 is a Phase 3 study that has not yet begun recruiting, run by Children's Hospital Los Angeles. The registered enrollment target is 150 participants.
The verdict
NCT06934655, a Phase 3 study, has not yet begun recruiting, sponsored by Children's Hospital Los Angeles.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutide 2.4 mg weekly for at least 3 months prior to surgery. Participants will be randomized to either (1) semaglutide 2.4 mg weekly or (2) standard care for 24 months. Primary, secondary, and tertiary outcomes will be assessed at multiple time points: 1-month, day of surgery, and 1-, 3-, 6-, 9-, 12-, 18-, and 24-months postoperatively. We hypothesize that early re-initiation of semaglutide will be safe, well-tolerated, and lead to greater improvements in obesity, cardiometabolic risk, and eating behaviors.
Interventions
- DRUG Semaglutide 2.4 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2026-06-01 |
| Est. Completion | 2033-11-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06934655
The ClinicalTrials.gov registry entry for NCT06934655 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Los Angeles, which has 119 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Semaglutide 2.4 mg is the first listed.
NCT06934655 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06934655 about?
NCT06934655 is a clinical study titled "Early Re-Initiation of Semaglutide Post Sleeve Gastrectomy in Youth". This is a Phase 3a, randomized, parallel-controlled trial designed to compare the early re-initiation of semaglutide, starting two weeks after sleeve gastrectomy, to standard care (no pharmacotherapy following surgery). The trial will involve 150 youth with severe obesity who have been on semaglutid...
What is the current status of trial NCT06934655?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2026-06-01. Estimated completion is 2033-11-01.
What interventions are being tested in trial NCT06934655?
The interventions under investigation include: Semaglutide 2.4 mg (DRUG).
Who is sponsoring clinical trial NCT06934655?
This trial is sponsored by Children's Hospital Los Angeles, which has 119 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.